Business
PainReform Commences Development for OcuRing™-K Phase II Trial, LayerBio’s Drop-Less Sustained-Release Ocular Therapy
Development plan positions OcuRing™-K for advancement in the fast-growing, multi-billion-dollar global cataract surgery marketTEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) today announced, through its pharmaceutical division, the commencement of its development plan for OcuRing™-K, LayerBio’s patented, drop-less, intraoperatively administered sustained-release ocular therapy designed to deliver controlled, site-specific release of ketorolac following cataract
About this update from Prf Technologies Ltd.
[{"type":"image","alt":"PainReform Ltd","displaySize":"","headline":null,"caption":"PainReform Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":283,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/b87767806c4b38224443db9a93a3dd0a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8rnf4Sfc87De6ZQ.vLH_qw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b87767806c4b38224443db9a93a3dd0a","width":283,"height":122}},"lazy":false},{"type":"text","content":"Development plan positions OcuRing™-K for advancement in the fast-growing, multi-billion-dollar global cataract surgery market","length":126,"tagName":"p"},{"type":"text","content":"TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) today announced, through its pharmaceutical division, the commencement of its development plan for OcuRing™-K, LayerBio’s patented, drop-less, intraoperatively administered sustained-release ocular therapy designed to deliver controlled, site-specific release of ketorolac following cataract surgery. Following the closing of PainReform’s majority investment in LayerBio and the integration of OcuRing-K into PainReform’s development portfolio, the Company conducted a methodical internal assessment with LayerBio’s management team to define development priorities and establish a clear path for advancing the program. Work is now progressing toward the Phase II clinical trial.","length":766,"tagName":"p"},{"type":"text","content":"OcuRing-K is an erodible, intraoperatively administered sustained-release device designed to provide extended and consistent intraocular therapeutic levels of an NSAID (non-steroidal, non-opiate, anti-inflammatory analgesic). LayerBio’s technology is designed to address major limitations of traditional postoperative eye-drop regimens, which typically require multiple daily steroid and NSAID drops for several weeks and deliver only a small fraction—often less than 5%—of the drug inside the eye. OcuRing-K is designed to eliminate this drop-dependent approach through a single, intraoperative, sustained-release therapy.","length":623,"tagName":"p"},{"type":"text","content":"This inefficient delivery of eye drops produces sharp fluctuations in drug levels, increasing the potential for inconsistent efficacy and side effects. In contrast, Oc...